📈 Stocks 🌍 United States

IHE vs. RSPH: Comparing 2026 Healthcare ETF Performance and Strategy

IHE outperforms RSPH in recent 1-year returns and lower drawdown, making it a preferred choice for investors seeking concentrated pharmaceutical exposure over broader, equal-weighted healthcare access.

📅 September 8, 2026 🕐 1 min read

3 assets impacted (Stocks). Net bias: 2 Bullish, 0 Bearish, 1 Neutral. Strongest signal: NVDA ↑ 10/10 (70% confidence).

📊 Affected Assets (3)

NVDA

Bullish 🤖 70%

🗓️ Long-term 🌍 US · Explicit

Referenced in promotional past performance context; no current opinion but bullish by example.

NFLX

Bullish 🤖 70%

🗓️ Long-term 🌍 US · Explicit

Referenced in promotional past performance context; no current opinion but bullish by example.

JNJ

Neutral 🤖 55%

📆 Mid-term 🌍 US · Explicit

Mentioned as a top holding in IHE; no direct sentiment expressed.

🎯 Key Takeaways

IHE delivers a 50% 1-year return compared to 29% for RSPH, with a lower 0.37% expense ratio.
IHE features high concentration, with its top 10 holdings accounting for 78% of assets, whereas RSPH offers a more balanced distribution.
IHE's lower 5-year maximum drawdown of 16% makes it a more resilient option for long-term investors compared to RSPH's 22%.

📝 Executive Summary

The iShares U.S. Pharmaceuticals ETF (IHE) and Invesco S&P 500 Equal Weight Health Care ETF (RSPH) offer distinct approaches to the healthcare sector. While IHE utilizes market-cap weighting with high concentration in industry giants, RSPH provides broader, equal-weighted exposure. Recent data favors IHE for its superior 1-year returns and lower volatility, positioning it as a compelling choice for 2026.

❓ FAQ

What is the primary difference between IHE and RSPH?

IHE is a market-cap-weighted fund focused specifically on the U.S. pharmaceutical sub-sector, while RSPH is an equal-weighted fund covering the broader S&P 500 healthcare sector.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article